Andy Haigh

Andrew (Andy) Haigh is an accomplished executive in the bioscience and healthcare sectors, currently serving as President and Chief Executive Officer at Adapsyn Bioscience since May 2016. In addition to this role, Andy holds the position of Board Member and Past Chair of the Emerging Company Advisory Board at BIOTECanada since June 2021. Previous experience includes serving as Director of Finance and Business Development at Forbius, where Andy played a key role as the second employee before its acquisition by Bristol Myers Squibb. Other notable positions include Senior Associate and Analyst at Lumira Capital Corp., Project Manager at HTX - The Health Technology Exchange, and Analyst at MaRS Discovery District. Andy Haigh holds an MBA in Finance and Healthcare from Ivey Business School at Western University and a Ph.D. in Biology from Dalhousie University.